Clinical Trial Update: A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase II multicenter, open-label, non-comparative study evaluating gefitinib (Iressa) with radiotherapy in patients with glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED